These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33324552)

  • 1. PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of
    Li Z; Lim SL; Tao Y; Li X; Xie Y; Yang C; Zhang Z; Jiang Y; Zhang X; Cao X; Wang H; Qian G; Wu Y; Li M; Fang F; Liu Y; Fu M; Ding X; Zhu Z; Lv H; Lu J; Xiao S; Hu S; Pan J
    Front Oncol; 2020; 10():574525. PubMed ID: 33324552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRD4 inhibitor MZ1 exerts anti-cancer effects by targeting MYCN and MAPK signaling in neuroblastoma.
    Zhang X; Guo X; Zhuo R; Tao Y; Liang W; Yang R; Chen Y; Cao H; Jia S; Yu J; Liao X; Li X; Fang F; Li G; Wu D; Xu Y; Li Z; Pan J; Wang J
    Biochem Biophys Res Commun; 2022 May; 604():63-69. PubMed ID: 35299072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ARV-825 Demonstrates Antitumor Activity in Gastric Cancer
    Liao X; Qian X; Zhang Z; Tao Y; Li Z; Zhang Q; Liang H; Li X; Xie Y; Zhuo R; Chen Y; Jiang Y; Cao H; Niu J; Xue C; Ni J; Pan J; Cui D
    Front Oncol; 2021; 11():753119. PubMed ID: 34733788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes.
    Wu S; Jiang Y; Hong Y; Chu X; Zhang Z; Tao Y; Fan Z; Bai Z; Li X; Chen Y; Li Z; Ding X; Lv H; Du X; Lim SL; Zhang Y; Huang S; Lu J; Pan J; Hu S
    Cancer Cell Int; 2021 Apr; 21(1):230. PubMed ID: 33888130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent targeting of MAP3K3 and BRD4 by
    Liu C; Gen Y; Tanimoto K; Muramatsu T; Inoue J; Inazawa J
    Mol Ther Nucleic Acids; 2021 Sep; 25():83-92. PubMed ID: 34258104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.
    Henssen A; Althoff K; Odersky A; Beckers A; Koche R; Speleman F; Schäfers S; Bell E; Nortmeyer M; Westermann F; De Preter K; Florin A; Heukamp L; Spruessel A; Astrahanseff K; Lindner S; Sadowski N; Schramm A; Astorgues-Xerri L; Riveiro ME; Eggert A; Cvitkovic E; Schulte JH
    Clin Cancer Res; 2016 May; 22(10):2470-81. PubMed ID: 26631615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARV-825 Showed Antitumor Activity against BRD4-NUT Fusion Protein by Targeting the BRD4.
    Yang L; Jing Y; Xia X; Yin X
    J Oncol; 2023; 2023():9904143. PubMed ID: 38130463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
    Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
    Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
    Saenz DT; Fiskus W; Qian Y; Manshouri T; Rajapakshe K; Raina K; Coleman KG; Crew AP; Shen A; Mill CP; Sun B; Qiu P; Kadia TM; Pemmaraju N; DiNardo C; Kim MS; Nowak AJ; Coarfa C; Crews CM; Verstovsek S; Bhalla KN
    Leukemia; 2017 Sep; 31(9):1951-1961. PubMed ID: 28042144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ARV-825-induced BRD4 protein degradation as a therapy for thyroid carcinoma.
    He L; Chen C; Gao G; Xu K; Ma Z
    Aging (Albany NY); 2020 Mar; 12(5):4547-4557. PubMed ID: 32163373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells.
    Sun B; Fiskus W; Qian Y; Rajapakshe K; Raina K; Coleman KG; Crew AP; Shen A; Saenz DT; Mill CP; Nowak AJ; Jain N; Zhang L; Wang M; Khoury JD; Coarfa C; Crews CM; Bhalla KN
    Leukemia; 2018 Feb; 32(2):343-352. PubMed ID: 28663582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRD4 degrader ARV-825 produces long-lasting loss of BRD4 protein and exhibits potent efficacy against cholangiocarcinoma cells.
    Lu Q; Ding X; Huang T; Zhang S; Li Y; Xu L; Chen G; Ying Y; Wang Y; Feng Z; Wang L; Zou X
    Am J Transl Res; 2019; 11(9):5728-5739. PubMed ID: 31632543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma.
    Jia SQ; Zhuo R; Zhang ZM; Yang Y; Tao YF; Wang JW; Li XL; Xie Y; Li G; Wu D; Chen YL; Yu JJ; Feng CX; Li ZH; Zhou RF; Yang RD; Yang PC; Zhou B; Wan XM; Wu YM; Jiao WY; Zhou NN; Fang F; Pan J
    J Immunol Res; 2022; 2022():7945884. PubMed ID: 36438198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the 'Undruggable' MYC in Pancreatic Cancer.
    Minko T
    Trends Pharmacol Sci; 2020 Oct; 41(10):684-686. PubMed ID: 32893006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: Preformulation studies, formulation development and in vitro evaluation.
    Rathod D; Fu Y; Patel K
    Eur J Pharm Sci; 2019 Oct; 138():105039. PubMed ID: 31394259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting bromodomain and extra-terminal proteins to inhibit neuroblastoma tumorigenesis through regulating MYCN.
    Shi X; Wang Y; Zhang L; Zhao W; Dai X; Yang YG; Zhang X
    Front Cell Dev Biol; 2022; 10():1021820. PubMed ID: 36187481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
    Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
    J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy.
    He Y; Ju Y; Hu Y; Wang B; Che S; Jian Y; Zhuo W; Fu X; Cheng Y; Zheng S; Huang N; Qian Z; Liu J; Zhou P; Gao X
    J Control Release; 2023 Feb; 354():155-166. PubMed ID: 36538950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
    Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
    J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
    Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
    Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.